Literature DB >> 18832029

Assessment of the influence factors on in vitro testing of nasal sprays using Box-Behnken experimental design.

Changning Guo1, Keith J Stine, John F Kauffman, William H Doub.   

Abstract

The purpose of the research was to investigate the influences of actuation parameters and formulation physical properties on nasal spray delivery performance using design of experiment (DOE) methodology. A 3-level, 4-factor Box-Behnken design with a total of 27 experimental runs was used in this study. Nine simulated aqueous formulations with different viscosities and surface tensions were prepared using carboxymethylcellulose sodium (CMC, gelling agent) and Tween80 (surfactant) each at three concentration levels. Four factors, actuation stroke length, actuation velocity, concentration of gelling agent, and concentration of surfactant were investigated for their influences on measured responses of shot weight, spray pattern, plume geometry and droplet size distribution (DSD). The models based on data from the DOE were then optimized by eliminating insignificant terms. Pfeiffer nasal spray pump units filled with the simulated formulations were used in the study. Nasal pump actuation stroke length exerts a strong, independent influence on shot weight, and also slightly affects spray pattern and plume geometry. Actuation velocity and concentration of gelling agent have significant effects on spray pattern, plume geometry and DSD, in a complicated manner through interaction terms. Concentration of surfactant has little, if any, influence on nasal spray characteristics. Results were fitted to quadratic models describing the inherent relationships between the four factors evaluated and nasal spray performance. The DOE study helped us to identify the source of variability in nasal spray product performance, and obtained better understanding in how to control the variability. Moreover, the quadratic models developed from the DOE study quantitatively describe the inherent relationships between the factors and nasal spray performance characteristics. With the assistance of the response surfaces developed from the DOE model, the time and labor in designing a nasal spray product to achieve desired product performance characteristics can be reduced.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18832029     DOI: 10.1016/j.ejps.2008.09.001

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  6 in total

1.  Assessment of the influence factors on nasal spray droplet velocity using phase-Doppler anemometry (PDA).

Authors:  Xiaofei Liu; William H Doub; Changning Guo
Journal:  AAPS PharmSciTech       Date:  2011-02-01       Impact factor: 3.246

2.  Importance of Spray-Wall Interaction and Post-Deposition Liquid Motion in the Transport and Delivery of Pharmaceutical Nasal Sprays.

Authors:  Arun V Kolanjiyil; Ali Alfaifi; Ghali Aladwani; Laleh Golshahi; Worth Longest
Journal:  Pharmaceutics       Date:  2022-04-28       Impact factor: 6.525

3.  Development of sustained-release microspheres for the delivery of SAR 1118, an LFA-1 antagonist intended for the treatment of vascular complications of the eye.

Authors:  Sarath Yandrapu; Uday B Kompella
Journal:  J Ocul Pharmacol Ther       Date:  2012-12-20       Impact factor: 2.671

4.  Characterization of stability and nasal delivery systems for immunization with nanoemulsion-based vaccines.

Authors:  Paul E Makidon; Shraddha S Nigavekar; Anna U Bielinska; Nicholas Mank; Abhishek M Shetty; Julie Suman; Jessica Knowlton; Andrzej Myc; Trent Rook; James R Baker
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-04       Impact factor: 2.849

5.  Development and evaluation of nanoemulsifying preconcentrate of curcumin for colon delivery.

Authors:  Jyoti Wadhwa; Abhay Asthana; Gyati Shilakari; Arun Kumar Chopra; Ranjit Singh
Journal:  ScientificWorldJournal       Date:  2015-03-11

6.  Analytical challenges and regulatory requirements for nasal drug products in europe and the u.s.

Authors:  Sabrina Trows; Klaus Wuchner; Rene Spycher; Hartwig Steckel
Journal:  Pharmaceutics       Date:  2014-04-11       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.